Immunotherapy Improves Overall Survival in Women With Genital Tract Melanoma
Source: Dermatology Advisor, May 2025
Overall survival (OS) in women with genital tract melanoma (GTM) is improved with immunotherapy, according to study findings published in Melanoma Research.
Data on the use of immunotherapy for mucosal melanomas overall has been lacking. As GTM in women is a rare condition, research regarding effective treatment in this patient population has been even more limited. Therefore, investigators explored the impact of immunotherapy on OS among women with GTM in the United States, as well as factors associated with OS.
The investigators conducted a retrospective cohort study using electronic health records from the National Cancer Database to identify patients diagnosed with invasive vaginal or vulvar melanoma between 2004 and 2019. The primary outcome was OS, defined as time from initial diagnosis to death or date of last contact. Multivariate Cox regression and Kaplan-Meier plots were used for statistical analysis. Patients with in-situ and/or stage 0 disease were excluded.